Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPB-111077 + Bendamustine + Rituximab in Relapsed/Refractory DLBCL
NCT04049825Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of OPB-111077 in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity at 23 days and Adverse Events up to 3 years. Started Nov 2019; status: completed.
02
Drugs
OPB-111077
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04049825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049825.